Penserra Capital Management LLC Zentalis Pharmaceuticals, Inc. Transaction History

Penserra Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$66.92 - $84.79 $68,927 - $87,333	-1,030 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$46.83 - $73.5 $4,214 - $6,615	90 Added 9.57%	1,030 $68,000
Q2 2021 Aug 12, 2021	BUY	$37.41 - $62.25 $935 - $1,556	25 Added 2.73%	940 $50,000
Q1 2021 May 13, 2021	SELL	$35.69 - $52.72 $535 - $790	-15 Reduced 1.61%	915 $39,000
Q4 2020 Feb 12, 2021	BUY	$31.71 - $57.97 $29,490 - $53,912	930 New	930 $48,000

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.